Cargill Puts Bold Innovation at Center of Effort to Decarbonize Shipping
Cargill is advancing a new era in sustainable shipping, putting innovation and collaboration at the core of its mission to move goods responsibly across the globe. Through wind-assisted propulsion technologies, dual-fuel methanol-powered vessels, and digital solutions, Cargill is setting the standard for helping the industry advance progress toward the International Maritime Organization’s (IMO) 2050 net-zero target. Combining technical expertise with a commitment to industry-wide partnerships, Cargill is helping to future-proof the maritime sector while enabling customers to meet their sustainability goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114753261/en/
“Decarbonizing shipping is a monumental task that requires courage, innovation, and collaboration,” said Jan Dieleman, president of Cargill’s Ocean Transportation business. “Our role extends beyond freight-shipping services; we aim to catalyze a shift across the industry toward sustainable practices. Through strategic investments in cutting-edge technology and robust partnerships, we are accelerating the journey to net-zero emissions in shipping.”
Innovating with Wind-Assisted Propulsion: The Pyxis Ocean and Beyond
Leading the charge in wind-assisted propulsion, the Pyxis Ocean—the first dry bulk vessel equipped with BAR Technologies’ WindWings®—completed its maiden voyage in 2023. WindWings are large, rigid sails that harness wind power to reduce fuel use and emissions.
In addition to WindWings, Cargill has expanded its wind-assisted technology program to include VentoFoil vertical suction sails on the NBA Magritte and rotor sails on the TR Lady. With these three vessels the company is experimenting and learning before scaling up technical, operational and commercial aspects. These technologies further utilize wind power to decrease fuel dependency and emissions, aligning with the IMO's target to have 5-10% of maritime energy from renewable sources by 2030.
Cargill believes that wind could make an important contribution to achieving decarbonization goals in the short, medium, and long term. Dieleman says that while the cost of fuels that could contribute to a zero-carbon future may remain high, developing, testing, and improving wind assisted propulsion technologies before these fuels are available could reduce reliance on them.
Transforming Fuels: Biofuels and Methanol-Powered Vessels
Alongside wind propulsion, Cargill is transforming fuel usage across its fleet. The company is pioneering biofuels made from renewable sources, such as fatty acid methyl esters (FAME), providing a drop-in fuel option to lower emissions without extensive engine modifications. In 2023, the company moved from trialing these fuels to frequent execution as it prepares to scale up. Nearly 172,000 metric tons of biofuel blends containing 63,000 metric tons of FAME was lifted in 2023. Cargill is also the first dry-bulk charterer to sign commercial agreements for dual-fuel methanol-powered ships, which are expected to be operational within the next two years. Methanol, a low-carbon alternative fuel, offers a scalable pathway to zero emissions. These methanol-powered vessels—the first of their kind in commercial service—highlight Cargill’s proactive approach in adopting sustainable fuel solutions to support both its own and its customers’ ambitious Scope 3 emissions reduction goals.
Harnessing Digital Solutions for Efficiency and Sustainability
Digital innovation is also central to Cargill ’s decarbonization efforts. Cargill is using advanced digital tools, including voyage optimization technologies, to create digital twins of its vessels. This enables optimal speed and route planning to reduce fuel consumption and emissions. Partnering with ZeroNorth, Cargill leverages these digital solutions to enhance operational efficiency and sustainability, reinforcing its commitment to data-driven progress toward net-zero.
Building a Sustainable Future Through Collaboration
Recognizing that decarbonizing the maritime industry requires a collaborative approach, Cargill partners across the sector to drive meaningful progress. As a founding member of the Maersk Mc-Kinney Moller Center for Zero Carbon Shipping, Cargill works with industry leaders to test and promote alternative fuels, including ammonia and methanol. Cargill is also a key player in the Sea Cargo Charter, a coalition dedicated to reducing shipping’s climate impact through transparency and shared decarbonization frameworks.
“As we continue this journey, we’re focused on solutions that don’t just improve our own operations but drive change across the industry,” added Dieleman. “Our vision is a shipping sector that delivers the goods the world needs while protecting our planet’s future. We’re proud to be part of this transformation and are committed to building a more sustainable future for global shipping.”
For additional information about Cargill’s efforts to decarbonize shipping, visit https://www.cargill.com/transportation/ocean-transportation-sustainability.
About Cargill
Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.
Our 160,000 team members innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 159 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114753261/en/
Contacts
Nicole Marlor
Cargill Media Relations
media@cargill.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom